Program Medium
Internet-based program

Method of Physician Participation Utilized in Learning Process
There are no fees for participating and receiving CME credit for this activity. During the July 29, 2022 through July 29, 2024, participants must 1) read the learning objectives and faculty disclosures; 2) study the educational activity, and are expected to view all 27 segments, totaling 3.0 hours, to successfully complete the activity and earn CME credit; 3) register and complete the evaluation form and post-test; 4) score 100% on the post-test; and 5) print out CME certificate.

Estimated Time to Complete Educational Activity
3.0 hours. Physicians must study the enduring activity, and are expected to view every segment to successfully complete the activity and earn CME credit.

Course Overview
In this web-based program, physicians will learn how recent developments in basic and clinical research have helped to advance the ability to optimize the management of Parkinson’s disease.

Release Date
July 29, 2022

Expiration Date
July 29, 2024

Intended Audience
This complimentary CME educational activity is designed for all healthcare providers (HCPs) involved in developing, delivering, consulting, and monitoring care for patients who may have or be at risk for Parkinson’s disease, including neurologists, movement disorder specialists, geriatricians, primary care physicians, family medicine specialists, nurse practitioners and related clinicians.

Registration
Participation in this iQ&A interactive Medical Intelligence Zone is complimentary, and clinicians are invited to view this CME-certified program and/or share this invitation with other colleagues, departmental staff members, and healthcare professionals.

Grantor Support
This activity is supported by an independent medical education grant from Avion Pharmaceuticals

Accreditation Statement
This activity has been planned and implemented in accordance with the Essential Areas and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the University of Massachusetts Medical School, Office of CME, and CMEducation Resources, LLC. The University of Massachusetts Medical School is accredited by the ACCME to provide continuing medical education for physicians.

Credit Designation Statement
The University of Massachusetts Medical School, Office of CME designates this enduring material for a maximum of 3.0 AMA PRA Category 1 Credits(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Policy on Faculty & Provider Disclosure
It is the policy of the University of Massachusetts Medical School, Office of CME to ensure fair balance, independence, objectivity and scientific rigor in all activities. All faculty participating in CME activities sponsored by the University of Massachusetts Medical School, Office of CME are required to present evidence-based data, identify and reference off-label product use and disclose all relevant financial relationships with those supporting the activity or others whose products or services are discussed. Faculty disclosure will be provided in the activity materials.

Program Faculty and Disclosure

Laxman Bahroo, DO, FAAN
Associate Professor, Department of Neurology
Georgetown University Medical Center
Vice Chair of Finance
Director, Residency Program
Director, Botulinum Toxin Clinic
Associate Professor of Neurology
Medstar Georgetown University Hospital
Washington, D.C.

Speaking and/or consulting: Abbvie, Acorda, Amneal, Avion, Ipsen, Supernus, Teva, Kyowa Kirin, and Neurocrine

John C. Morgan, MD, PhD
Professor and Director
Movement & Memory Disorder Programs
Department of Neurology
Medical College of Georgia
Augusta University
Augusta, Georgia

Nothing to disclose

Hubert Fernandez, MD
Center for Neurological Restoration
Professor of Medicine (Neurology)
Cleveland Clinic Lerner College of Medicine
Case Western Reserve University
Neurological Institute, Cleveland Clinic
Cleveland, Ohio

Advisor or consultant for: BIAL Neurology; Biopas; Cerevel; CNS Ratings; Covance; Kyowa Hakko Kirin; Partners Healthcare System; Sun Pharmaceutical Industries; Sunovion Research Development Trust Grants for clinical research from: Alkahest; Amneal; Biogen

Program Managers and Web Editor Disclosure
Program Manager Gideon Bosker, MD and Denise Leary have nothing to disclose.

Educational Objectives

Upon completion of this activity, participants will be able to:

• Understand the disease burden, clinical presentation, and initial treatment options for Parkinson’s disease (PD);
• Initiate carbidopa/levodopa (CD/LD)-based treatment options based on patient preferences, stage of disease, and severity of symptoms;
• Discuss the initial sequencing of therapy for PD, including the rationale for treatments that offer dose and timing flexibility to optimize symptom stability and reduce OFF time associated with narrowing therapeutic window of CD/LD associated with disease progression;
• Assess the clinical success and shortfalls of self-titrating CD/LD formulations—including mechanical, technical, and practical use aspects of scored formulations—including assessment of including patient satisfaction with the regimen, ease of self-titration, and related outcomes;
• Detail the role, rationale, pharmaco-equivalence, and trial-based/clinical evidence for various established and investigational CD/LD formulations, including those based on fractionated dosing that permit self-titration through a scoring-based mechanism;
• Compare LD/CD formulations, their composition, the mechanical and dosing-related aspects of administration, and how to educate patients in the use of fractionated dosing preparations;
• Identify persons with PD who are appropriate candidates for CD/LD-based treatment, and specifically, identify patients who are ideal candidates for self-titration based on ON-OFF profiles and progression of motor symptoms;
• Educate patients about the expected clinical/symptom-related improvements to be expected with CD/LD formulations and how to titrate, dose, and make adjustments to formulations that permit fractionated dosing;
• Translate current knowledge about the dopamine-related pathophysiology of PD to the selection of CD/LD-based therapies

Hardware and Software Requirements:
To participate in this program, viewers must have a PC or Macintosh computer that has active, ongoing internet access for the duration of the program, as well as a compatible Flash-viewer. An email address is required for registration, and a printer is required to print out the CME certificate.

Privacy Policy
When you participate in a CME activity offered by CMEducation Resources, we ask you for your name, degree, affiliation, street address, telephone number, fax number, and/or e-mail address (the "Information"). We use that Information in the following ways:

• completion, we will give the Information to that company for that purpose only.
• For each CME activity that you take, you must complete an evaluation questionnaire. That questionnaire asks if you are willing to participate in a follow-up survey. If you answer yes, we will use your name and contact information to send you the survey.
• We may use the Information to send you information about other CME activities that CMEducation Resources is offering.
• If our company is acquired by or merged into another company, we may make the Information available to the new owner/entity to use in the ways described above, to enable it to continue our business.
• You should check this privacy policy periodically to see whether we have made any changes.

Disclaimer

Copyright © 2022 by CMEducation Resources, LLC All rights reserved.

Reproduction, distribution, or translation without express written permission is strictly prohibited.

Content on this webcast reflects the opinions, output, and analyses of experts, investigators, educators, and clinicians whose activities for, while independent, are commercially supported by the sponsor noted at the start of each activity.

Content on this webcast is not meant to be, nor substitute for national guidelines or recommendations generated by professional, academic societies, colleges, or associations.

Content on this webcast is intended for educational value only. Its contents, analyses, and any recommendation made herein are intended to make scientific information and opinion available to health professionals, to stimulate thought, and further investigation. This webcast is not designed nor is any aspect of the contents here intended to provide advice regarding medical diagnosis or treatment for any individual case. Any decisions regarding diagnosis and/or management of any individual patient or group of patients should be made on individual basis after having consulted appropriate sources, whether they be appropriate consultants and/or guidelines and recommendations issued by national organizations, professional societies, governmental health organizations, or similar bodies. This webcast is not intended for use by the layman.

Opinions expressed herein are not necessarily those of Pharmatecture, LLC, CMEducation Resources, LLC, program supporters or accreditors, but reflect the opinions and analyses of the experts who have authored the material. Mention of products or services does not constitute endorsement. Clinical, legal, financial, and other comments are offered for general guidance only; and professional counsel should be sought for all specific situations.

Copyright © CMEducation Resources, LLC